Response to comment on "Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics".
Journal
Science translational medicine
ISSN: 1946-6242
Titre abrégé: Sci Transl Med
Pays: United States
ID NLM: 101505086
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
entrez:
1
12
2021
pubmed:
2
12
2021
medline:
1
4
2022
Statut:
ppublish
Résumé
Triangulation of evidence from clinical trials and human genetics suggests a potential excess risk of cardiovascular disease events arising from therapeutic inhibition of sclerostin.
Identifiants
pubmed: 34851696
doi: 10.1126/scitranslmed.abf4530
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Comment
Langues
eng
Sous-ensembles de citation
IM
Pagination
eabf4530Subventions
Organisme : British Heart Foundation
ID : FS/18/23/33512
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 202922/Z/16/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00017/1
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RE/13/1/30181
Pays : United Kingdom
Organisme : NICHD NIH HHS
ID : P50 HD028138
Pays : United States
Organisme : Wellcome Trust
ID : 104085/Z/14/Z
Pays : United Kingdom
Organisme : Cancer Research UK
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_14135
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00011/1
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_13049
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 088158/Z/09/Z
Pays : United Kingdom
Commentaires et corrections
Type : CommentOn
Type : CommentOn